NEXT: description, rationale, and evaluation of a novel internet-based mail-delivered syringe service program.

Autor:	Hayes BT; Division of General Internal Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA., Favaro J; NEXT Harm Reduction, New York, NY, USA., Behrends CN; Population Health Sciences, Weill Cornell Medicine, New York, NY, USA., Coello D; NEXT Harm Reduction, New York, NY, USA., Jakubowski A; Division of General Internal Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA., Fox AD; Division of General Internal Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA.
Jazyk:	angličtina
Zdroj:	Journal of substance use [J Subst Use] 2024; Vol. 29 (1), pp. 129-135. Date of Electronic Publication: 2022 Nov 11.
DOI:	10.1080/14659891.2022.2144500
Abstrakt:	Background: Despite proven health benefits, harm reduction services provided through in-person syringe services programs (SSPs) and pharmacies are largely unavailable to most people who inject drugs (PWID). Internet-based mail-delivered harm reduction services could overcome barriers to in-person SSPs. This manuscript describes Needle Exchange Technology (NEXT) Harm Reduction, the first formal internet-based mail delivery SSP in the US. Methods: We examined the trajectory of NEXT's growth between February 2018 and August 2021. Descriptive statistics were used to characterize program participants. All analysis were run using STATA statistical software. Results: Over the course of 42 months, 1,669 unique participants enrolled in NEXT. The program distributed 1,648,162 total syringes with a median of 79,449 syringes per month. Most participants ordered multiple times (61%); 31% had more 5 or more orders (upper range = 48 orders). The total number of syringes per month and total number of first-time syringe orders per month increased steadily over time, particularly after the onset of the COVID-19 pandemic. Conclusions: The online platform and mail-delivery model appears successful in reaching PWID at high risk for harms from IDU. Changes to state laws and additional funding support are needed to make mail-delivery harm reduction more widely available throughout the US.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu